Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
By the end of April 2021, more than five million people in the United States, or about eight percent of the population, had not received the second dose of the experimental mRNA Pfizer/BioNTech or Moderna/NIAID COVID-19 vaccines being distributed under an Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA).
If you ask the average person about how they think the SARS-CoV-2 virus came about, chances are they will say something like: “It started with an infected bat in a wet market in Wuhan, China and somehow managed to get into humans.” That is the theory that consistently has been promoted by many scientists and public health officials since the World Health Organization (WHO) declared a COVID-19 pandemic.
Health experts now say that PCR testing for SARS-CoV-2, the virus associated with the illness COVID-19, is too sensitive and needs to be adjusted to rule out people who have insignificant amounts of the virus in their system.1 The test’s threshold is so high that it detects people with the live virus as well as […]